

## REMARKS

Applicants provisionally elect Group I, claim 5 and linking claims 1-4 and 8-10 with traverse. Applicants respectfully observe that the Examiner has indicated the presence of linking claims that claim "the subject matter which the applicant regards as his invention." 35 U.S.C. §112, second paragraph. Examination of all these claims and claims dependent therefrom in the present application is therefore deemed proper. Clearly since the claims are so linked, no serious burden can properly be said to exist. Withdrawal of the Restriction Requirement is respectfully requested.

At pages 5 and 6 of the Office Action Applicant is required under 35 U.S.C. §121 to elect a single species for initial prosecution. Elections a) through d) were requested. Applicants respectfully elect: a) AP-1 as candidate cis-acting regulatory element; b) luciferase as a specific reporter gene; c) a specific regulatory is not deemed applicable; and d) an immature dendritic cell as a specific immunocyte. Claims 1-5 and 8-10 are deemed to be readable thereon.

Please charge any fee involved to Deposit Account No. 18-1982. The Commissioner is hereby authorized to charge any additional fees which may be required by this paper, or credit any overpayment to Account No. 18-1982.

Respectfully submitted,

/George S. Jones/

George S. Jones (Reg. No. 38,508)  
Attorney for Applicant

sanofi-aventis U.S. Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (908) 231-3776  
Telefax (908) 231-2626

Docket No. USAV2002/0244 US PCT